| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Clio Dessinioti | |
| Christina Antoniou | |||
| Alexander J Stratigos | |||
| Petros P Sfikakis | |||
| Athina Matekovits | |||
| Aikaterini-Evaggelia Moustou | |||
| P2860 | cites work | Drug-induced lupus erythematosus | Q56753224 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 486-504 | |
| P577 | publication date | 2009-07-22 | |
| P1433 | published in | Journal of the American Academy of Dermatology | Q15757046 |
| P1476 | title | Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review | |
| P478 | volume | 61 |
| Q41812742 | A Case of Palmoplantar Pustulosis Induced by Certolizumab Pegol: New Anti-TNF-alpha Demonstrates the Same Class Effect. |
| Q37901281 | Amicrobial pustulosis-like rash in a patient with Crohn's disease under anti-TNF-alpha blocker |
| Q38018812 | An update of the role of nutritional therapy in the management of Crohn's disease. |
| Q38112476 | Atypical ulcers |
| Q38630959 | Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. |
| Q88248400 | Biologic Agent-Associated Cutaneous Adverse Events: A Single Center Experience |
| Q41120913 | Biologics in dermatology: adverse effects |
| Q37972243 | Chilblain lupus induced by TNF-α antagonists: a case report and literature review. |
| Q39361308 | Clinical Signs, Pathophysiology and Management of Cutaneous Side Effects of Anti-Tumor Necrosis Factor Agents. |
| Q33735385 | Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patients |
| Q41098795 | Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience |
| Q97886676 | Dermatomyositis-lupuslike syndrome overlap under treatment with etanercept for rheumatoid arthritis |
| Q51565778 | Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels. |
| Q34809425 | Effect of short-term partial enteral nutrition on the treatment of younger patients with severe Crohn's disease |
| Q56747640 | Eosinophilia during Psoriasis Treatment with TNF Antagonists |
| Q50512877 | Etanercept-induced cutaneous and pulmonary sarcoid-like granulomas resolving with adalimumab. |
| Q42489757 | Exaggerated imiquimod application site reactions in the context of systemic tumor necrosis factor-alpha inhibition: more than a coincidental occurrence? |
| Q38315640 | Immune-mediated reactions to anti-tumor necrosis factors in inflammatory bowel disease |
| Q42674160 | Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study |
| Q37924648 | Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations |
| Q24186928 | Interventions for chronic palmoplantar pustulosis |
| Q34722599 | Large Vessel Vasculitis Occurring in Rheumatoid Arthritis Patient under Anti-TNF Therapy |
| Q28072729 | Lipodystrophy in Insulin-Treated Subjects and Other Injection-Site Skin Reactions: Are We Sure Everything is Clear? |
| Q33914479 | Lung sarcoidosis in etanercept treated rheumatoid arthritis patient: a case report and review of the literature |
| Q39690095 | New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases. |
| Q36214266 | Nodular Vasculitis That Developed during Etanercept (Enbrel) Treatment in a Patient with Psoriasis. |
| Q36904729 | Paradoxes in dermatology |
| Q49970991 | Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients |
| Q90438132 | Paradoxical psoriasis induced by TNF-α blockade shows immunological features typical of the early phase of psoriasis development |
| Q37960534 | Pharmacodynamics of TNF-α inhibitors in psoriasis |
| Q33939033 | Psoriasis, anti-tumor necrosis factor therapy, and tuberculosis: report of three challenging cases and literature review |
| Q48118262 | Pyoderma gangrenosum and pyogenic arthritis presenting as severe sepsis in a rheumatoid arthritis patient treated with golimumab |
| Q37902251 | Recent advances in cytokines in cutaneous and systemic lupus erythematosus |
| Q37980484 | Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis |
| Q37223800 | Sarcoid panuveitis associated with etanercept treatment, resolving with adalimumab |
| Q35625482 | Severe Henoch-Schönlein purpura with infliximab for ulcerative colitis |
| Q38663608 | Skin Signs of Rheumatoid Arthritis and its Therapy-Induced Cutaneous Side Effects |
| Q37894193 | TNF alpha antagonist therapy and safety monitoring |
| Q37867162 | TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists |
| Q36453770 | TNFα inhibitor induced lupus-like syndrome (TAILS) in a patient with IBD. |
| Q55070918 | The Effect of TNF-α on Regulatory T Cell Function in Graft-versus-Host Disease. |
| Q38700961 | The Immune Response and the Pathogenesis of Idiopathic Inflammatory Myositis: a Critical Review |
| Q42635096 | The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis |
| Q46710832 | Therapeutic benefits of natural ingredients for atopic dermatitis |
| Q34008773 | Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs |
| Q38973692 | Trigger factors of cutaneous lupus erythematosus: a review of current literature. |
| Q37654068 | Tumor Necrosis Factor Alpha Blocker-Induced Erythrodermic Sarcoidosis in with Juvenile Rheumatoid Arthritis: A Case Report and Review of the Literature |
| Q36513081 | Vasculitis associated with tumor necrosis factor-α inhibitors |
| Q84279866 | [Etanercept and infections] |
| Q84279884 | [Psoriasiform skin reactions during treatment with etanercept] |
| Q64043064 | [What's new in clinical dermatology?] |
Search more.